Filing summary
Identity note: The request names Chiron Real Estate Inc., but the supplied Form 10-K is for Global Medical REIT Inc. (NYSE: GMRE; preferred shares: GMRE PrA). Confirm the issuer before relying on this summary.
Business context and reporting period
This is Global Medical REIT Inc.’s annual report for the fiscal year ended December 31, 2021, filed March 1, 2022; it reports full-year results, not standalone fourth-quarter results. The company is an internally managed healthcare-property REIT. At year-end it owned 105 facilities with 4.34 million leasable square feet and approximately $103.1 million of annualized base rent. Its portfolio is primarily medical office buildings, and most facilities are leased to single tenants.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $115.9 million | $93.7 million |
| Net income (loss) | $18.3 million | $(2.5) million |
| Net income (loss) attributable to common stockholders | $11.8 million; $0.19 per share | $(7.7) million; $(0.17) per share |
| FFO per share and unit | $0.90 | $0.56 |
| AFFO per share and unit | $0.95 | $0.88 |
| Cash flow from operating activities | $69.0 million | $34.5 million |
| Cash and restricted cash at year-end | $12.8 million, including $7.2 million unrestricted cash | $10.8 million |
| Total debt, net of issuance costs | $571.7 million | $586.6 million |
| Total equity, including noncontrolling interest | $637.6 million | $457.8 million |
Rental revenue was $115.8 million. Interest expense was $19.7 million; the weighted-average interest rate on debt was 2.87% at year-end. Common dividends were $0.82 per share for 2021, versus $0.80 in 2020; the Series A preferred dividend rate was 7.50% annually.
Material changes versus the prior year
- Revenue increased $22.2 million, primarily from acquisitions completed in 2021 and a full year of revenue from properties acquired in 2020.
- Net income improved by $20.8 million. The comparison is affected by $14.0 million of one-time management-internalization expense in 2020 and a $1.1 million property-sale gain in 2021.
- Operating cash flow increased $34.4 million. Investing cash outflow was $194.7 million, while financing cash inflow was $127.7 million.
- The company completed 20 acquisitions for a contractual purchase price of $189.1 million, and issued common stock through a public offering and ATM program. Year-end common shares outstanding rose to 64.9 million from 49.5 million.
- The credit facility was amended in May 2021, increasing total capacity to $750 million, extending maturities, and converting the facility to unsecured debt. Net debt declined year over year, while total equity increased substantially.
Outlook, risks, and unusual items
- No formal quantified earnings or acquisition guidance is provided. Management cited an aging population and the shift toward outpatient care as potential supports, while noting increased competition for acquisitions and higher interest rates as headwinds.
- Management estimated that a 100-basis-point increase in LIBOR on the year-end unhedged floating-rate debt would increase annual interest expense by approximately $1.7 million. The company hedged the $350 million term loan, but disclosed uncertainty around the transition from LIBOR to SOFR and potential hedge-basis risk.
- COVID-19 had not materially affected the company’s liquidity or operating and financial performance through the filing date, according to management. However, healthcare staffing shortages and tenant labor costs remained risks.
- Tenant, industry, and geographic concentrations are material: the three largest tenants accounted for 19.4% of annualized base rent; Texas represented 19.1%, and Florida 10.7%. Leases representing 16.2% of annualized base rent expire in 2024. Year-end vacancy was approximately 2.5% of leasable square feet.
- In 2022, the company had approximately $17.7 million of scheduled principal and interest payments and up to approximately $24 million of capital improvement obligations. Its Series A preferred stock, with a $77.6 million liquidation preference, becomes redeemable by the company beginning September 2022.
- A proposed sale of a Belpre, Ohio property for approximately $44.6 million remained subject to due diligence and closing contingencies; completion was expected no earlier than June 2022. A Prescott, Arizona property sale generated a $1.1 million gain in 2021.
- The filing reports no material pending litigation and no known environmental liability expected to materially affect the company. The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; the acquisition valuation process was identified as a critical audit matter.
Most important facts to verify
- Confirm issuer identity: the supplied filing is Global Medical REIT Inc., not Chiron Real Estate Inc.
- Review debt covenants, maturity schedule, available revolver capacity, and the LIBOR-to-SOFR transition; verify the company’s ability to meet refinancing and liquidity needs.
- Assess tenant credit quality, lease expirations, state concentration, and the implications of single-tenant properties and healthcare reimbursement or staffing pressures.
- Evaluate the sustainability of common and preferred dividends against operating cash flow, AFFO, capital commitments, and potential preferred-stock redemption.
- Confirm completion and proceeds from the proposed Belpre sale, the status of acquisitions under contract, and the dilution and use of proceeds from equity issuances.